27 Stocks Moving in Monday’s Pre-Market Session
Gainers
Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday.
Expert Ratings For Editas Medicine
Editas Medicine (NASDAQ:EDIT) has observed the following analyst ratings within the last quarter:
SVB Leerink Maintains Market Perform on Editas Medicine, Lowers Price Target to $27
SVB Leerink analyst Rick Bienkowski maintains Editas Medicine (NASDAQ:EDIT) with a Market Perform and lowers the price target from $41 to $27.
Editas Medicine Q4 EPS $(0.61) Beats $(0.72) Estimate, Sales $12.47M Beat $4.29M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.72) by 15.28 percent. This is a 39 percent increase over losses of $(1.00) per share from the
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Editas Suddenly Terminates Chief Medical Officer Without An Explanation
Editas Medicine Inc (NASDAQ: EDIT) has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company.
35 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Society Pass Incorporated (NASDAQ: SOPA) gained 63.4% to $3.45 after dropping 16% on Monday.